Table 1 Baseline socio-demographic characteristics of the 239 study participants diagnosed with invasive cervical cancer by HIV status (JUTH and LUTH combined)
From: Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria
Characteristic | HIV Negative, N = 192 | HIV Positive, N = 47 | p-value |
|---|---|---|---|
Age at enrollment (Years) |  |  |  < 0.001 |
 Median (IQR) | 57 (45, 66) | 46 (40, 51) |  |
 Missing | 7 | 0 |  |
BMI (Kg/M2) | Â | Â | 0.46 |
 Median (IQR) | 25 (22, 30) | 25 (21, 28) |  |
 Missing | 25 | 4 |  |
Age at first live birth | Â | Â | 0.86 |
 Median (IQR) | 20.0 (19.0, 22.0) | 20.0 (18.0, 23.0) |  |
 Missing | 27 | 6 |  |
Total number of childbirth (live birth) | Â | Â | 0.034 |
 0 | 7 (3.9%) | 2 (4.3%) |  |
 1–3 | 35 (19.6%) | 17 (37.0%) |  |
 4 +  | 137 (76.5%) | 27 (58.7%) |  |
 Missing | 13 | 1 |  |
Age at first intercourse | Â | Â | 0.84 |
 Median (IQR) | 18.0 (16.0, 20.0) | 18.0 (16.0, 20.0) |  |
 Missing | 25 | 2 |  |
Total number of sexual partners in lifetime |  |  |  < 0.001 |
 Median (IQR) | 1.00 (1.00, 2.00) | 3.00 (1.00, 4.00) |  |
 Missing | 40 | 6 |  |
Treated for sexually transmissible infection (STI/STD) |  |  |  < 0.001 |
 No | 81 (58.7%) | 8 (22.2%) |  |
 Yes | 57 (41.3%) | 28 (77.8%) |  |
 Missing | 54 | 11 |  |
Highest level of education completed | Â | Â | 0.006 |
 No formal education | 59 (32.6%) | 5 (10.6%) |  |
 Primary | 42 (23.2%) | 15 (31.9%) |  |
 Secondary | 38 (21.0%) | 18 (38.3%) |  |
 Tertiary | 42 (23.2%) | 9 (19.1%) |  |
 Missing | 11 | 0 |  |
Cervical cancer screening history | Â | Â | 0.005 |
 No | 4 (2.1%) | 6 (12.8%) |  |
 Yes | 188 (97.9%) | 41 (87.2%) |  |
Cervical cancer screening test history | Â | Â | 0.33 |
 No | 18 (25.7%) | 8 (36.4%) |  |
 Yes | 52 (74.3%) | 14 (63.6%) |  |
 Missing | 122 | 25 |  |
Age at first cervical cancer screening | Â | Â | 0.061 |
 Median (IQR) | 50 (42, 59) | 45 (35, 47) |  |
 Missing | 145 | 34 |  |
FIGO staging at diagnosis | Â | Â | 0.066 |
 Advanced | 68 (47.9%) | 24 (64.9%) |  |
 Not advanced | 74 (52.1%) | 13 (35.1%) |  |
 Missing | 50 | 10 |  |
Histopathological type | Â | Â | 0.70 |
 Adenocarcinoma | 11 (8.2%) | 1 (4.2%) |  |
 Squamous cell carcinoma | 108 (80.6%) | 19 (79.2%) |  |
 Other | 15 (11.2%) | 4 (16.7%) |  |
 Missing | 58 | 23 |  |
Tumor histologic grading | Â | Â | 0.60 |
 Well-differentiated | 11 (13.6%) | 3 (23.1%) |  |
 Moderately differentiated | 56 (69.1%) | 8 (61.5%) |  |
 Poorly differentiated | 14 (17.3%) | 2 (15.4%) |  |
 Missing | 111 | 34 |  |
Type of ICC treatment received | Â | Â | 0.29 |
 Chemoradiation only | 15 (27.3%) | 1 (6.7%) |  |
 Chemotherapy only | 1 (1.8%) | 1 (6.7%) |  |
 Extended hysterectomy and chemoradiation | 2 (3.6%) | 1 (6.7%) |  |
 Extended hysterectomy and chemotherapy | 15 (27.3%) | 4 (26.7%) |  |
 Palliative care | 7 (12.7%) | 4 (26.7%) |  |
 Other | 15 (27.3%) | 4 (26.7%) |  |
 Missing | 137 | 32 |  |
Diabetes mellitus | Â | Â | 0.38 |
 No | 155 (90.1%) | 42 (95.5%) |  |
 Yes | 17 (9.9%) | 2 (4.5%) |  |
 Missing | 20 | 3 |  |
Hypertension | Â | Â | 0.034 |
 No | 112 (63.3%) | 36 (80.0%) |  |
 Yes | 65 (36.7%) | 9 (20.0%) |  |
 Missing | 15 | 2 |  |
Kidney Disease |  |  |  > 0.99 |
 No | 160 (98.2%) | 42 (97.7%) |  |
 Yes | 3 (1.8%) | 1 (2.3%) |  |
 Missing | 29 | 4 |  |
Follow-up (months) | Â | Â | 0.041 |
 Median (IQR) | 8 (0, 21) | 2 (0, 10) |  |
 Missing | 83 | 20 |  |
Survival status | Â | Â | 0.30 |
 Alive | 109 (79.0%) | 27 (71.1%) |  |
 Died | 29 (21.0%) | 11 (28.9%) |  |
 Missing | 54 | 9 |  |